Gut Barriers and Maternal Antibodies Explain Patchy Rotavirus Vaccine Success

Rotavirus vaccines stand among the great public health achievements of the past two decades. Before their introduction, rotavirus was the leading cause of severe dehydrating diarrhea in infants and young children worldwide, killing hundreds of thousands each year. In countries that adopted routine infant immunization, hospital admissions for rotavirus gastroenteritis collapsed, and childhood deaths from the virus fell dramatically. Yet the same vaccines that perform so impressively in high-income settings deliver far weaker protection in many low- and middle-income countries, precisely where the burden of rotavirus mortality is heaviest. A new review published in PLOS Pathogens by Sarah Woodyear, Nabila Nawar Binti and Sarah L. Caddy examines why oral rotavirus vaccines behave so differently across the globe, assembling evidence on maternal antibodies, gut health, co-infections, co-vaccinations and human genetics into a coherent account of a persistent immunological inequity.

The central paradox is that rotavirus vaccines are given orally, which means they must replicate in the infant intestine to stimulate immunity. Live attenuated vaccine viruses are swallowed, infect cells lining the small intestine, and mimic a natural infection without causing disease. This replication triggers both antibodies and local T cell responses at the mucosal surface, the front line of defense against a virus that attacks the gut. Any factor that interferes with vaccine virus replication therefore blunts the immune response. In high-income countries, vaccine take is robust: most infants seroconvert, developing measurable antibody responses after two or three doses. In many parts of Africa and Asia, by contrast, the same or similar vaccine formulations induce protective responses in a substantially smaller fraction of recipients, leaving a large proportion of children vulnerable to severe disease despite being fully vaccinated.

One of the best-documented explanations involves maternal antibodies. Pregnant women transfer immunoglobulin G across the placenta, arming newborns with passive immunity against pathogens they have encountered. Mothers also pass antibodies to their infants through breast milk, particularly secretory immunoglobulin A, which coats the intestinal lining. These maternal antibodies can neutralize vaccine virus in the infant gut before it has a chance to infect enough cells to prime the immune system. The review highlights that this interference may be exacerbated in low- and middle-income countries for two reasons. First, women in high-transmission settings have experienced more natural rotavirus infections over their lifetimes, so they carry higher circulating and mucosal antibody levels to pass on. Second, breastfeeding practices differ: prolonged and exclusive breastfeeding, which carries many other benefits, means infants continue receiving antibody-rich milk throughout the vaccination window, sustaining the inhibitory pressure on oral vaccine replication.

The evidence for maternal antibody interference is not merely circumstantial. Studies have correlated higher titers of transplacentally acquired antibodies and breast milk antibody concentrations with reduced vaccine immunogenicity, and some trials have explored delaying vaccination or manipulating feeding around the time of dosing to see whether responses improve. The relationship is complex, because breast milk also contains other bioactive components, including antimicrobial proteins and factors that shape the developing gut microbiome, so the net effect of breastfeeding on vaccine performance is not uniformly negative. Nevertheless, the review argues that in settings where both maternal antibody levels and breastfeeding duration are high, passive immunity represents a significant and underappreciated barrier to successful oral vaccination, one that helps explain why infants in the highest-burden countries respond least well to the current vaccines.

Beyond maternal antibodies, the overall health of the infant gut emerges as a decisive factor. Malnutrition, widespread in many resource-limited regions, impairs the immune system in multiple ways, reducing the capacity of intestinal immune cells to respond to stimulation and compromising the structural integrity of the gut barrier. Environmental enteric dysfunction, a chronic inflammatory condition of the small intestine common among children in settings with poor sanitation and repeated microbial exposure, flattens the villi that absorb nutrients and alters the cellular landscape that vaccine viruses must infect. A gut in this state is a hostile environment for an attenuated live vaccine: inflammation accelerates the turnover of intestinal epithelial cells, shortening the window in which vaccine virus can replicate, and the damaged mucosa mounts aberrant immune responses that fail to generate durable protection against rotavirus.

The gut microbiome adds another layer of complexity. The trillions of microbes colonizing the infant intestine do not merely coexist with the immune system; they actively train it. Early-life microbial colonization influences the development of mucosal lymphoid tissue, the balance of inflammatory and regulatory responses, and even the expression of antiviral genes in epithelial cells. Disruption of this microbial community, through malnutrition, antibiotic exposure, recurrent infections or poor sanitation, can leave the gut immune system poorly calibrated for responding to an oral vaccine. The review emphasizes that the relative contributions of malnutrition, microbiome disruption and environmental enteric dysfunction vary by geography, so no single intervention will correct the problem everywhere. In one region, nutritional supplementation may be the dominant lever; in another, sanitation and microbial restoration may matter more.

Competition from other oral vaccines and concurrent enteric infections provides further interference, and both are more prevalent in resource-limited settings. The oral poliovirus vaccine, given on schedules that often overlap with rotavirus vaccination, replicates in the same intestinal niche and can interfere with rotavirus vaccine take, an interaction documented in trials where the two vaccines were co-administered. Meanwhile, infants in high-burden environments are frequently infected with other enteric pathogens, including bacteria, parasites and other viruses, at the very time they are being immunized. These co-infections can crowd out vaccine virus, provoke inflammatory responses that disrupt mucosal immunity, or redirect the immune system’s attention away from rotavirus. The cumulative effect is that an infant in a low-income setting may face a gauntlet of biological obstacles to oral vaccination that an infant in a wealthy country rarely encounters.

Host genetics introduces a less obvious but increasingly well-supported variable. Rotavirus entry into intestinal cells depends on histo-blood group antigens, carbohydrate structures on the cell surface whose synthesis is governed by fucosyltransferase genes. Different human populations carry different frequencies of polymorphisms in these genes, and these variants determine which histo-blood group antigens an individual’s gut expresses. Because particular rotavirus strains, and by extension particular vaccine strains, show preferences for certain antigen types, an infant’s genotype can influence how readily the vaccine virus infects intestinal cells and stimulates immunity. The review highlights that these genetic differences across populations further modulate vaccine immunogenicity, adding a layer of biological variation that cannot be addressed through delivery or nutrition alone and that may partly explain geographic patterns of vaccine failure.

A crucial theme running through the review is that none of these factors acts in isolation. Maternal antibodies, nutritional status, microbiome composition, environmental enteric dysfunction, co-infections, co-vaccinations and host genetics interact to shape the gut environment and collectively limit oral vaccine replication. A malnourished infant in a high-transmission setting may simultaneously face high maternal antibody levels, a dysbiotic microbiome, an inflamed intestine, competing enteric infections and a genotype less permissive to the vaccine strain. The result is a multiplicative, not merely additive, reduction in vaccine effectiveness. This systems-level view reframes the problem: rather than searching for a single silver bullet, researchers and public health programs must consider how multiple determinants converge in specific populations and design interventions accordingly.

The path forward, the authors argue, requires context-specific strategies that combine several approaches. Optimized vaccine scheduling, including adjustments to the timing and number of doses relative to breastfeeding patterns and co-vaccinations, could reduce interference in some settings. Nutritional interventions and microbiome-targeted therapies may restore the gut environment to a state more conducive to oral vaccine replication. Ultimately, however, the review points toward the development of novel vaccine platforms capable of overcoming the unique immunological challenges of low- and middle-income countries, whether through injectable formulations that bypass the gut’s inhibitory environment, engineered vaccine strains resistant to neutralization, or adjuvanted approaches that strengthen mucosal responses. Closing the rotavirus vaccine equity gap is not only a scientific challenge but a moral imperative, given that the children least protected by current vaccines are those at greatest risk of dying from the disease the vaccines were designed to prevent.

Subject of Research: Determinants of variable rotavirus vaccine effectiveness across global settings

Article Title: Why does rotavirus vaccine effectiveness vary around the globe?

Article References: Why does rotavirus vaccine effectiveness vary around the globe?. (n.d.). https://doi.org/10.1371/journal.ppat.1014670

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014670

Keywords: rotavirus, vaccine effectiveness, maternal antibodies, gut microbiome, environmental enteric dysfunction, malnutrition, oral poliovirus vaccine, histo-blood group antigens, fucosyltransferase, low- and middle-income countries, mucosal immunity, PLOS Pathogens